Buys | $7,500,000 | 1 | 3 |
Sells | $2,899,823 | 30 | 97 |
Manning Paul B | director | 1 | $7.5M | 0 | $0 | $7.5M |
Schoch Charles | See Remarks | 0 | $0 | 4 | $267,781 | $-267,781 |
Nichols William Garrett | Chief Medical Officer | 0 | $0 | 5 | $356,318 | $-356,318 |
Barone Francesca | Chief Scientific Officer | 0 | $0 | 5 | $477,223 | $-477,223 |
Aguilar-Cordova Estuardo | 10 percent owner | 0 | $0 | 6 | $486,476 | $-486,476 |
Tyagarajan Seshu | Chief Technology Officer | 0 | $0 | 5 | $491,658 | $-491,658 |
Tak Paul Peter | Chief Executive Officer | 0 | $0 | 5 | $820,367 | $-820,367 |
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of …
Over the last 12 months, insiders at Candel Therapeutics, Inc. have bought $7.5M and sold $2.9M worth of Candel Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Candel Therapeutics, Inc. have bought $7.46M and sold $2.9M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Manning Paul B (director) — $7.5M.
The last purchase of 1,250,000 shares for transaction amount of $7.5M was made by Manning Paul B (director) on 2024‑12‑16.
2025-01-15 | Sale | Tak Paul Peter | Chief Executive Officer | 21,704 0.0476% | $7.22 | $156,811 | +1.63% | |
2025-01-15 | Sale | Barone Francesca | Chief Scientific Officer | 13,534 0.0297% | $7.22 | $97,783 | +1.63% | |
2025-01-15 | Sale | Tyagarajan Seshu | Chief Technology Officer | 14,322 0.0314% | $7.22 | $103,476 | +1.63% | |
2025-01-15 | Sale | Nichols William Garrett | Chief Medical Officer | 10,428 0.0229% | $7.22 | $75,342 | +1.63% | |
2025-01-15 | Sale | Schoch Charles | See Remarks | 9,511 0.0209% | $7.22 | $68,717 | +1.63% | |
2025-01-08 | Sale | Tak Paul Peter | Chief Executive Officer | 21,172 0.0454% | $8.22 | $173,996 | -7.50% | |
2025-01-08 | Sale | Barone Francesca | Chief Scientific Officer | 13,673 0.0293% | $8.22 | $112,367 | -7.50% | |
2025-01-08 | Sale | Tyagarajan Seshu | Chief Technology Officer | 14,545 0.0312% | $8.22 | $119,534 | -7.50% | |
2025-01-08 | Sale | Nichols William Garrett | Chief Medical Officer | 10,799 0.0231% | $8.22 | $88,749 | -7.50% | |
2025-01-08 | Sale | Schoch Charles | See Remarks | 9,971 0.0214% | $8.22 | $81,944 | -7.50% | |
2024-12-16 | Manning Paul B | director | 1.25M 3.786% | $6.00 | $7.5M | +34.09% | ||
2024-11-29 | Sale | Tak Paul Peter | Chief Executive Officer | 48,847 0.1456% | $4.56 | $222,527 | +71.44% | |
2024-11-29 | Sale | Barone Francesca | Chief Scientific Officer | 22,081 0.0658% | $4.56 | $100,592 | +71.44% | |
2024-11-29 | Sale | Tyagarajan Seshu | Chief Technology Officer | 20,392 0.0608% | $4.56 | $92,898 | +71.44% | |
2024-11-29 | Sale | Nichols William Garrett | Chief Medical Officer | 13,935 0.0415% | $4.56 | $63,482 | +71.44% | |
2024-10-15 | Sale | Aguilar-Cordova Estuardo | 10 percent owner | 10,412 0.0279% | $6.03 | $62,784 | +18.74% | |
2024-10-14 | Sale | Aguilar-Cordova Estuardo | 10 percent owner | 15,000 0.0401% | $6.02 | $90,300 | +17.67% | |
2024-10-11 | Sale | Aguilar-Cordova Estuardo | 10 percent owner | 15,000 0.0403% | $6.05 | $90,750 | +16.45% | |
2024-10-03 | Sale | Aguilar-Cordova Estuardo | 10 percent owner | 1,800 0.0055% | $6.85 | $12,330 | +1.27% | |
2024-10-02 | Sale | Aguilar-Cordova Estuardo | 10 percent owner | 26,988 0.083% | $6.92 | $186,757 | -0.88% |
Manning Paul B | director | 1303752 2.9314% | $11.5M | 3 | 0 | <0.0001% |
Tak Paul Peter | Chief Executive Officer | 251912 0.5664% | $2.22M | 3 | 5 | <0.0001% |
Barone Francesca | Chief Scientific Officer | 110673 0.2488% | $976,135.86 | 1 | 5 | <0.0001% |
Tyagarajan Seshu | Chief Technology Officer | 96790 0.2176% | $853,687.80 | 2 | 5 | <0.0001% |
Martell Christopher | director | 152000 0.3418% | $1.34M | 3 | 0 | <0.0001% |
$84,871,118 | 57 | 17.71% | $397.96M | |
$24,384,691 | 42 | -30.27% | $432.05M | |
$109,415,500 | 33 | 18.13% | $377.78M | |
$26,923,982 | 20 | -17.22% | $407.13M | |
Candel Therapeutics, Inc. (CADL) | $14,865,077 | 18 | -28.56% | $392.27M |
Increased Positions | 52 | +173.33% | 13M | +198.34% |
Decreased Positions | 11 | -36.67% | 60,779 | -0.91% |
New Positions | 21 | New | 8M | New |
Sold Out Positions | 2 | Sold Out | 14,876 | Sold Out |
Total Postitions | 71 | +136.67% | 20M | +197.43% |
Fmr Llc | $34,331.00 | 9.34% | 3.92M | +4M | +59,592.67% | 2024-12-31 |
Baker Bros. Advisors Lp | $26,092.00 | 7.1% | 2.98M | +3M | New | 2024-12-31 |
Acorn Capital Advisors, Llc | $16,972.00 | 4.62% | 1.94M | +2M | New | 2024-12-31 |
Northpond Ventures, Llc | $16,933.00 | 4.61% | 1.94M | 0 | 0% | 2024-09-30 |
Braidwell Lp | $14,000.00 | 3.81% | 1.6M | +2M | New | 2024-12-31 |
Vanguard Group Inc | $11,718.00 | 3.19% | 1.34M | +392,885 | +41.52% | 2024-12-31 |
Blackrock, Inc. | $10,360.00 | 2.82% | 1.18M | +58,268 | +5.18% | 2024-12-31 |
Portolan Capital Management, Llc | $6,595.00 | 1.8% | 753,745 | +753,745 | New | 2024-12-31 |
Halter Ferguson Financial Inc. | $5,962.00 | 1.62% | 681,334 | +376,795 | +123.73% | 2024-12-31 |
State Street Corp | $4,908.00 | 1.34% | 560,969 | +68,964 | +14.02% | 2024-12-31 |